We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

94 hedge funds and large institutions have $207M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more call options, than puts

Call options by funds: $3.56M | Put options by funds: $1.25M

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

3% more funds holding

Funds holding: 91 → 94 (+3)

29% less capital invested

Capital invested by funds: $291M → $207M (-$83.2M)

38% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 34

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
94
Holders Change
+3
Holders Change %
+3.3%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
10
Increased
21
Reduced
34
Closed
7
Calls
$3.56M
Puts
$1.25M
Net Calls
+$2.32M
Net Calls Change
+$436K

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$5.55M
2
BlackRock
BlackRock
New York
+$1.42M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.12M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.04M
5
Russell Investments Group
Russell Investments Group
United Kingdom
+$942K

Top Sellers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.72M
2
CS
Credit Suisse
Switzerland
-$1.7M
3
GCP
GSA Capital Partners
United Kingdom
-$1.14M
4
UBS Group
UBS Group
Switzerland
-$900K
5
JP Morgan Chase
JP Morgan Chase
New York
-$793K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
1
Ameriprise
Minnesota
$39.4M +$5.55M +17,613 +13%
6CM
2
683 Capital Management
New York
$23.8M – – –
BlackRock
3
BlackRock
New York
$22.2M +$1.42M +4,522 +6%
VC
4
Vivo Capital
California
$15.9M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$14.4M +$390K +1,238 +2%
Citadel Advisors
6
Citadel Advisors
Florida
$7.88M -$623K -1,978 -6%
IVM
7
InterWest Venture Management
California
$6.77M – – –
KCM
8
Knoll Capital Management
Florida
$6.14M – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4.96M +$1.04M +3,301 +21%
State Street
10
State Street
Massachusetts
$4.52M +$132K +420 +3%
Goldman Sachs
11
Goldman Sachs
New York
$4.5M -$412K -1,307 -7%
CAM
12
Cormorant Asset Management
Massachusetts
$3.54M – – –
Assenagon Asset Management
13
Assenagon Asset Management
Luxembourg
$3.47M -$1.72M -5,449 -29%
PAWC
14
P.A.W. Capital
Connecticut
$3.36M -$210K -666 -5%
Northern Trust
15
Northern Trust
Illinois
$3.31M -$608K -1,929 -13%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$3M -$537K -1,703 -13%
DC
17
Davenport & Co
Virginia
$2.5M +$31.5K +100 +1%
DMK
18
David M. Knott
$2.45M -$194K -617 -6%
TMC
19
Trellus Management Company
Florida
$2M +$206K +653 +9%
SCM
20
Soleus Capital Management
Connecticut
$1.89M +$292K +926 +15%
WMSA
21
Weiss Multi-Strategy Advisers
New York
$1.77M +$25.8K +82 +1%
ACM
22
Altium Capital Management
New York
$1.75M – – –
LCM
23
Laurion Capital Management
New York
$1.62M -$728K -2,311 -28%
Two Sigma Investments
24
Two Sigma Investments
New York
$1.58M -$681K -2,162 -27%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$1.48M -$388K -1,230 -18%
1
2 3 4 5

EIGR Hedge Fund Activity: Q1 2021 in Review

94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2021, worth a combined $207M — down 29% from $291M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EIGR positions and 7 closed out — a net gain of 3 holders — while 21 added to existing stakes and 34 trimmed.

The largest buyer was Ameriprise, adding an estimated $5.55M. The largest seller was Assenagon Asset Management, cutting an estimated $1.72M.

  • 94 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2021, up from 91 in Q4 2020.
  • Funds reported $207M of Eiger BioPharmaceuticals, Inc. stock for Q1 2021, down 29% quarter-over-quarter.
  • 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2021 and 7 closed out, a net change of +3 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2021 was Ameriprise, an estimated $5.55M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2021 was Assenagon Asset Management, an estimated $1.72M sold.

Based on aggregated 13F filings for Q1 2021.